Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?

Healthcare investors often grapple with selecting between businesses that offer steady growth or those that have the potential to benefit from improving industry conditions. Two companies that represent contrasting approaches are Abbott Laboratories (NYSE:ABT) and Thermo Fisher Scientific (NYSE:TMO). Abbott (NYSE:ABT) continues to drive broad-based growth across diagnostics, medical devices, and nutrition, while Thermo Fisher (NYSE:TMO) appears to be benefiting from the early signs of improvement in the life sciences sector.

Abbott's (NYSE:ABT) strongest growth driver this quarter came from its diagnostics segment, which reported a 42% increase in sales to $3.09 billion in fiscal Q2, surpassing the estimated $3.02 billion. This segment's growth is primarily driven by the expansion of the colorectal cancer screening test, Cologuard, which has gained both new and repeat users.

Moreover, Abbott's cancer diagnostics business, integrated through the acquisition of Exact Sciences, has contributed significantly to this growth. The company's medical device business also contributes to its balanced earnings profile, making it a more resilient investment option.

On the other hand, Thermo Fisher Scientific (NYSE:TMO) relies heavily on the recovery of the life sciences industry. The company reported a 5% increase in organic revenue, which represents progress but still remains below the double-digit growth rate it previously achieved. Thermo Fisher's recovery is closely tied to the performance of pharmaceutical and biotechnology industries.

If spending by these customers continues to be delayed, the recovery could prove less durable than initially expected. The company's guidance increase also raises expectations for future execution, requiring Thermo Fisher to demonstrate that the recovery in customer spending is sustainable.

In summary, Abbott Laboratories (NYSE:ABT) offers a diversified healthcare business with multiple growth engines, while Thermo Fisher Scientific (NYSE:TMO) focuses on the improving life sciences industry. The choice between the two depends on investors' risk tolerance and their expectations for the recovery in the life sciences sector.